최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Bioscience, biotechnology, and biochemistry, v.81 no.11, 2017년, pp.2178 - 2185
Cha, Ji-Yun (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicine Research Institute, Wonkwang University, Iksan, Jeollabuk-do, Republic of Korea) , Jeon, Yong-Deok (Department of Oriental Medicine Resources, Chonbuk National University, Iksan, Jeollabuk-do, Republic of Korea) , Xin, Mingjie (EastHill Co., Gwonseon-gu, Suwon, Gyoenggi-do, Republic of Korea) , Kim, Do-Kuk (National Institute of Horticultural and Herbal Science, RDA, Jeonju, Jeollabuk-do, Republic of Korea) , Lee, Hoon-Yeon (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicine Research Institute, Wonkwang University, Iksan, Jeollabuk-do, Republic of Korea) , Kim, Bo-Ram (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicine Research Institute, Wonkwang University, Iksan, Jeollabuk-do, Republic of Korea) , Hwang, Sung-Woo (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicine Research Institute, Wonkwang University, Iksan, Jeollabuk-do, Republic of Korea) , Kim, Dae-Ki (Department of Immunology and Institute of Medical Science, Chonbu) , Jin, Jong-Sik , Lee, Young-Mi
AbstractThe aim of this study is to examine the anti-inflammatory effect of Euphorbia supina (ES) ethanol extract in dextran sulfate sodium (DSS)-induced experimental colitis model. ES was per orally administered at different doses of 4 or 20 mg/kg body weight with 5% DSS in drinking water for 7 day...
J. Immunology Andoh 183 1 687 2009 10.4049/jimmunol.0804169 Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease
J. Gastroenterol Sands 42 1 16 2007 10.1007/s00535-006-1995-7 Inflammatory bowel disease : past, present, and future
J. Gastroenterol Mizoguchi 43 1 1 2008 10.1007/s00535-007-2111-3 Inflammatory bowel disease, past, present and future : lessons from animal models
Inflamm bowel dis Hanauer 12 supple S3 2006 10.1097/01.MIB.0000195385.19268.68 Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities
Gut Rutgeerts 51 2 152 2002 10.1136/gut.51.2.152 Protagonist: Crohn’s disease recurrence can be prevented after ileal resection
Digestion Nagura 63 1 12 2001 10.1159/000051905 The immuno-inflammatory mechanism for tissue injury in inflammatory bowel disease and Helicobacter pylori-infected chronic active gastritis. Roles of the mucosal immune system
Clin Exp Immunol Ludwiczek 138 2 323 2004 10.1111/cei.2004.138.issue-2 Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease
N. engl. J. Med Podolsky 325 14 417 1991 10.1056/NEJM199110033251406 Inflammatory bowel disease
Dig Liver Dis Danese 37 11 811 2005 10.1016/j.dld.2005.03.013 Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation
Int Immunopharmacol Kumar 11 6 724 2011 10.1016/j.intimp.2011.01.022 Embelin ameliorates dextran sodium sulfate-induced colitis in mice
World J gastroenterol Xu 10 16 2311 2004 10.3748/wjg.v10.i16.2311 Drug therapy for ulcerative colitis
Keio J Med Matsuoka 63 4 69 2014 10.2302/kjm.2014-0006-RE Fecal microbiota transplantation for gastrointestinal diseases
World J Gastroenterol Chen 20 42 15657 2014 10.3748/wjg.v20.i42.15657 Enteric microbiota leads to new therapeutic strategies for ulcerative colitis
Am J Gastroenterol Kelly 109 7 1065 2014 10.1038/ajg.2014.133 Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients
J Crohns Colitis Langhorst 9 1 86 2015 10.1093/ecco-jcc/jju007 Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases
Aliment Pharmacol Ther Ng 38 8 854 2013 10.1111/apt.2013.38.issue-8 Systematic review: the efficacy of herbal therapy in inflammatory bowel disease
World J Gastroenterol Wan 20 39 14099 2014 10.3748/wjg.v20.i39.14099 Advances in treatment of ulcerative colitis with herbs: from bench to bedside
J Ethnopharmacol Wang 148 2 655 2013 10.1016/j.jep.2013.05.025 Vasorelaxant action of an ethylacetate fraction of Euphorbia humifusa involves NO-cGMP pathway and potassium channels
Curr Pharm Des Ogata 9 14 1107 2003 10.2174/1381612033455035 Cytokine and anti-cytokine therapies for inflammatory bowel disease
Annu Rev Med Papadakis 51 589 2000 10.1146/annurev.med.51.1.289 Role of cytokines in the pathogenesis of inflammatory bowel disease
Gastroenterology Sartor 106 2 533 1994 10.1016/0016-5085(94)90614-9 Cytokines in intestinal inflammation: pathophysiological and clinical considerations
Gastroenterology Malizia 100 1 150 1991 10.1016/0016-5085(91)90595-C Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease
Gastroenterology Simmonds 103 1 186 1992 10.1016/0016-5085(92)91112-H Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease
Gut Rachmilewitz 36 5 718 1995 10.1136/gut.36.5.718 Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn’s disease
Dig Dis Sci Murthy 38 9 1722 1993 10.1007/BF01303184 Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporine
Gastroenterology Okayasu 98 3 694 1990 10.1016/0016-5085(90)90290-H A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice
Curr Mol Pharmacol Dharmani 1 3 195 2008 10.2174/1874467210801030195 Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key
Evid Based Complement Alternat Med Wu 2011 525462 2011 10.1093/ecam/neq040 Protective effect of anthocyanins extract from blueberry on TNBS-induced IBD model of mice
Clin Immunol Ishiguro 120 3 335 2006 10.1016/j.clim.2006.05.010 Macrophage migration inhibitory factor has a proinflammatory activity via the p38 pathway in glucocorticoid-resistant ulcerative colitis
Gastroenterology Sandborn 122 6 1592 2002 10.1053/gast.2002.33426 Biologic therapy of inflammatory bowel disease
Paediatr Drugs Rufo 8 5 279 2006 10.2165/00148581-200608050-00002 Current therapy of inflammatory bowel disease in children
Prostaglandins Other Lipid Mediat Morita 68-69 165 2002 10.1016/S0090-6980(02)00029-1 Distinct functions of COX-1 and COX-2
Adv Exp Med Biol Lauritsen 371B 1301 1995 Effects of mesalazine on the formation of lipoxygenase and cyclooxygenase products
Cell Death Differ Perkins 13 5 759 2006 10.1038/sj.cdd.4401838 Good cop, bad cop: the different faces of NF-κB
Genes Dev Hayden 18 18 2195 2004 10.1101/gad.1228704 Signaling to NF-κB
Biochim Biophys Acta Kovacs-Nolan 1820 11 1753 2012 10.1016/j.bbagen.2012.07.007 The PepT1-transportable soy tripeptide VPY reduces intestinal inflammation
Cell Locksley 104 4 487 2001 10.1016/S0092-8674(01)00237-9 The TNF and TNF receptor superfamilies: integrating mammalian biology
Expert Opin Ther Targets Rose-John 11 5 613 2007 10.1517/14728222.11.5.613 The IL-6/sIL-6R complex as a novel target for therapeutic approaches
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.